A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

NCT06690281 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped PI left NIH.

Conditions

Gastrointestinal Carcinoma
Pancreatic Cancer
Hepatocellular Cancer
Cholangiocarcinoma
Duodenal Cancer
Colorectal Cancer
Small Bowel Cancer
Metastatic Cancers

Interventions

BIOLOGICAL: KRAS TCR-Transduced PBL
DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

National Cancer Institute (NCI)